65,437 trials
CNS Embryonal Tumor, Not Otherwise Specified · Malignant Glioma · Recurrent Atypical Teratoid/Rhabdoid Tumor
Primary: Maximum Tolerated Dose of Ribociclib and Everolimus — 120; 1.2 mg/m^2/day
ADHD
Primary: Number of High-effort Selections in the Effort-based Decision Making Task — 16.4; 21.35; 20.45; 19.8 Number of high-effort selections
Spinal Stenosis, Lumbar Region · Spondylolisthesis
Primary: Mean Total Length of Operative Time — 218; 218.5 minutes
Foot Ulcer, Diabetic · Infection
Primary: Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 69; 41; 36 percentage of subjects
RSV Illness in ≤12 Months of Participants
Primary: Respiratory Syncytial Virus (RSV) Load in the Upper Respiratory Tract as Measured by Quantitative Real Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) at…
Ankle Inversion Sprain · Chronic Instability of Joint
Primary: ML COP Velocity From Baseline to Post Intervention — 119.91; 118.91; 121.07; 116.99 % modulation — p=0.824
Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response Up to Week 16 - Investigational Treatment Period — 0; 0; 0; 0 Percentage of…
End-stage Renal Failure · Graft Rejection
Primary: Patient Survival With a Functioning Graft — 92.3; 96 percent of participants — p=0.26
Schizophrenia
Primary: Change in Verbal Memory Scores From Baseline to 4 Hours Post-Treatment — 53.90; 40.49; 53.03; 38.49 score on a scale
Obesity
Primary: Percentage of Patients With at Least 5% Weight Loss. — 80; 62 Participants — p=0.0352
Psoriasis Vulgaris
Primary: Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind…
Familial Chylomicronemia Syndrome · Lipoprotein Lipase Deficiency · Hyperlipoproteinemia Type 1
Primary: Mean Percent Change From Baseline in Fasting Triglyceride (TG) — -59.8; -49.2; -64.9; -45.5 percent change
Plaque Psoriasis
Primary: PASI 75 Response After 12 Weeks of Treatment — 39; 34; 4 Participants — p=<0.0001
G6PD Deficiency
Primary: Sensitivity of SD Biosensor POC G6PD Test for Identifying G6PD Deficient Individuals — 100.0; 100.0 percentage of participants
Colorectal Cancer Metastatic
Primary: Overall Response Rate — 0 participants